Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Oct 26, 2011, 06:22 ET from Reportlinker

NEW YORK, Oct. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0661209/Acute-Coronary-Syndrome-ACS-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global ACS therapeutics market. The report identifies the key trends shaping and driving the global ACS therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global ACS sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the ACS therapeutics market. Its scope includes -

- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) ACS therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Factor Xa inhibitors, P2Y (12) receptor antagonists, platelet aggregation inhibitors, CETP inhibitors and ADP receptor antagonists.

- Analysis of the current and future competition in the global TBI market. Key market players covered GlaxoSmithKline, The Medicine Company, Sanofi, Bayer AG/ Johnson & Johnson (J&J), F. Hoffmann-La Roche, Anthera Pharmaceuticals, Portola Pharmaceuticals/Novartis AG and Eisai Co., Ltd.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ACS therapeutics market.

- Analysis of key recent licensing and partnership agreements in ACS therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global ACS therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ACS therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global sepsis therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 7

2 Acute Coronary Syndrome (ACS) Therapeutics Market: Executive Summary 9

2.1 The ACS Therapeutics Market is Estimated to grow at a Compound Annual Growth Rate (CAGR) of 0.6% from 2010 to 2018 9

2.2 Current Competition in the ACS Therapeutics Market is Weak 10

2.3 High Unmet Needs Exist in the ACS Therapeutics Market in terms of Efficacy and Safety can be Addressed by Strong Pipeline with Many Novel First-in-class Molecules 12

2.4 Late Stage Development Failure Poses Threat to Market Growth 12

3 ACS Therapeutics: Introduction 13

3.1 Overview 13

3.1.1 ACS classification - 13

3.2 Epidemiology 14

3.3 Etiology 15

3.4 Symptoms 16

3.5 Diagnosis 16

3.5.1 12-lead ECG 17

3.5.2 Biomarkers 18

3.5.3 Chest Pain Observation Protocols 19

3.5.4 Imaging techniques 19

3.6 Treatment Algorithm of ACS 20

3.6.1 Treatment for the Symptoms of ACS – 21

3.6.2 Treatment for the Cause of ACS 21

3.6.3 Primary and Secondary Prevention 24

3.7 GlobalData Pipeline Report Guide 29

4 ACS Therapeutics: Market Characterization 31

4.1 Overview 31

4.2 ACS Therapeutics Market Size (2005-2010) – Global 31

4.3 ACS Therapeutics Market Forecast (2010-2018) – Global 33

4.4 ACS Therapeutics Market – The US (2005-2010) 34

4.5 ACS Therapeutics Market Forecast – The US (2010-2018) 35

4.6 ACS Therapeutics Market – France (2005-2010) 37

4.7 ACS Therapeutics Market Forecast – France (2010-2018) 38

4.8 ACS Therapeutics Market – Germany (2005-2010) 39

4.9 ACS Therapeutics Market Forecast - Germany (2010-2018) 40

4.10 ACS Therapeutics Market – Italy (2005-2010) 41

4.11 ACS Therapeutics Market Forecast – Italy (2010-2018) 42

4.12 ACS Therapeutics Market – Spain (2005-2010) 44

4.13 ACS Therapeutics Market Forecast – Spain (2010-2018) 45

4.14 ACS Therapeutics Market – The UK (2005-2010) 46

4.15 ACS Therapeutics Market Forecast – The UK (2010-2018) 48

4.16 ACS Therapeutics Market - Japan (2005-2010) 49

4.17 ACS Therapeutics Market Forecast – Japan (2010-2018) 50

4.18 Drivers and Barriers for the Acute Coronary Syndrome Market 51

4.18.1 Drivers for the ACS Therapeutics Market 52

4.18.2 Barriers for the ACS Therapeutics Market 53

4.19 Opportunity and Unmet Need 53

4.20 Key Takeaway 56

5 ACS Therapeutics: Competitive Assessment 57

5.1 Overview 57

5.2 Strategic Competitor Assessment 57

5.3 Product Profile for the Major Marketed Products in the ACS Therapeutics Market 58

5.3.1 Nitrates 58

5.3.2 Beta-adrenergic Receptor Blockers (Beta Blockers) 59

5.3.3 Calcium Channel Blockers 60

5.3.4 Angiotensin Converting Enzyme Inhibitor (ACE inhibitors) 60

5.3.5 Statins 61

5.3.6 Glycoprotein IIb/IIIa inhibitor 63

5.3.7 Lovenox (enoxaparin sodium injection) 69

5.3.8 Plavix (clopidogrel bisulfate) 71

5.3.9 Effient (prasugrel) 73

5.3.10 Brilinta (ticagrelor) 76

5.4 Key Takeaway 80

6 ACS Therapeutics: Pipeline Assessment 81

6.1 Overview 81

6.2 Strategic Pipeline Assessment 81

6.3 ACS Therapeutics Market – Promising Drugs under Clinical Development 85

6.4 Molecule Profile for Promising Drugs under Clinical Development 86

6.4.1 A-002 (varespladib Methyl) 86

6.4.2 Darapladib (SB-480848) 87

6.4.3 Dalcetrapib (RO4607381/Jtt-705) 89

6.4.4 Xarelto (rivaroxaban) 90

6.4.5 Otamixaban 91

6.4.6 Elinogrel 91

6.4.7 Cangrelor 93

6.5 ACS Therapeutics Market – Clinical Pipeline by Mechanism of Action 94

6.5.1 ACS Therapeutics – Phase III Clinical Pipeline 96

6.5.2 ACS Therapeutics – Phase II Clinical Pipeline 97

6.5.3 ACS Therapeutics – Phase I Clinical Pipeline 97

6.5.4 ACS Therapeutics – Discovery and Preclinical Pipeline 97

6.6 Key Takeaway 98

7 ACS Therapeutics: Clinical Trials Mapping 99

7.1 Clinical Trials by Region/Country (the US, EU5 & Japan) 99

7.2 Clinical Trials by Phase of Clinical Development 100

7.3 Clinical Trials by Trial Status 101

7.4 Clinical Trials by Sponsors 102

7.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials 104

8 ACS Therapeutics: Strategic Assessment 106

8.1 Key Events Impacting the Future Market 106

8.2 Future Market Competition Scenario 106

9 ACS Therapeutics: Future Players 109

9.1 Introduction 109

9.1.1 GlaxoSmithKline Plc 109

9.1.2 F. Hoffmann-La Roche 111

9.1.3 Anthera Pharmaceuticals 112

9.1.4 Novartis A G 112

9.1.5 Sanofi 114

9.1.6 Johnson & Johnson 115

9.1.7 Bayer AG 116

9.1.8 The Medicines Company 118

9.1.9 Eisai Co., Ltd. 120

9.1.10 Portola Pharmaceuticals, Inc. 123

9.1.11 Tabular Presentation Details of Other Companies in the Pipeline 124

10 ACS Therapeutics: Licensing and Partnership Deals 128

11 ACS Therapeutics: Appendix 130

11.1 Definitions 130

11.2 Acronyms 130

11.3 Methodology 131

11.3.1 Coverage 131

11.3.2 Secondary Research 132

11.3.3 Forecasting 132

11.3.4 Primary Research 135

11.3.5 Expert Panel Validation 136

11.4 Contact Us 136

11.5 Disclaimer 136

11.6 Bibliography 137

List of Tables

Table 1: Biochemical Cardiac Markers of the Evaluation and Management of Patients with Suspected ACS but Without ST-Segment Elevation on 12-Lead ECG 22

Table 2: Cardiac and Non-Cardiac Conditions that can Mimic Non-St-Elevation Acute Coronary Syndomes 23

Table 3: Recommendations for Diagnosis and Risk Stratification 23

Table 4: Recommendations for Oral Antiplatelet Agents 26

Table 5: Pharmacotherapy for ACS (STEMI and NSTEMI) 30

Table 6: ACS Therapeutics Market, Global, Revenue ($m), 2005–2010 36

Table 7: ACS Therapeutics Market, Global, Forecast ($m), 2010–2018 37

Table 8: ACS Therapeutics Market, The US, Forecast ($m), 2005–2010 38

Table 9: ACS Therapeutics Market, The US, Forecast ($m), 2010–2018 39

Table 10: ACS Therapeutics Market, France, Revenue ($m), 2005–2010 41

Table 11: ACS Therapeutics Market, France, Forecast ($m), 2010–2018 42

Table 12: ACS Therapeutics Market, Germany, Revenue ($m), 2005–2010 43

Table 13: ACS Therapeutics Market, Germany, Forecast ($m), 2010–2018 44

Table 14: ACS Therapeutics Market, Italy, Revenue ($m), 2005–2010 45

Table 15: ACS Therapeutics Market, Italy, Forecast ($m), 2010–2018 47

Table 16: ACS Therapeutics Market, Spain, Revenue ($m), 2005–2010 48

Table 17: ACS Therapeutics Market, Spain, Forecast ($m), 2010–2018 49

Table 18: ACS Therapeutics Market, The UK, Revenue ($m), 2005–2010 50

Table 19: ACS Therapeutics Market, The UK, Forecast ($m), 2010–2018 52

Table 20: ACS Therapeutics Market, Japan, Revenue ($m), 2005–2010 53

Table 21: ACS Therapeutics Market, Japan, Forecast ($m), 2010–2018 54

Table 22: Major Marketed Products Comparison in ACS Therapeutics Market, 2011 80

Table 23: Comparison of P2Y12 Inhibitors 81

Table 24: P2Y12 Clinical Studies 82

Table 25: ACS Therapeutics – Most Promising Drugs Under Clinical Development, 2010 88

Table 26: ACS Therapeutics – Phase III Clinical Pipeline, 2011 99

Table 27: ACS Therapeutics – Phase II Clinical Pipeline, 2011 100

Table 28: ACS Therapeutics – Phase I Clinical Pipeline, 2011 100

Table 29: ACS Therapeutics – Discovery and Preclinical Pipeline, 2011 100

Table 30: ACS Therapeutics, Global, Clinical Trials, 2011 102

Table 31: ACS Therapeutics, Global, Clinical Trials by Phase, 2011 103

Table 32: ACS Therapeutics, Global, Clinical Trials by Status of Development, 2011 104

Table 33: ACS Therapeutics, Global, Prominent Sponsors, 2011 106

Table 34: ACS Therapeutics, Global, Top Ten Companies by Phase, 2011 107

Table 35: GlaxoSmithKline - Pipeline Products 114

Table 36: Anthera Pharmaceuticals Company - Pipeline Products 115

Table 37: Novartis A G Company - Pipeline Products 117

Table 38: Sanofi – - Pipeline Products 118

Table 39: Johnson and Johnson Company – - Pipeline Products 119

Table 40: Bayer AG – - Pipeline Products 121

Table 41: The Medicines Company - Pipeline Products 123

Table 42: Eisai - - Pipeline Products 126

Table 43: The Medicines Company - Pipeline Products 126

Table 44: Other Companies in Pipeline, ACS Therapeutics, 2011 128

Table 45: ACS Therapeutics, Global, Deals, 2010 131

List of Figures

Figure 1: ACS Therapeutics, Global, Revenue and Market Forecast ($m), 2005–2018 13

Figure 2: Opportunity and Unmet Need in the ACS Therapeutics Market 14

Figure 3: ACS – Understanding the ACS 17

Figure 4: Plaque Formation and Atherosclerosis 19

Figure 5: Spectrum of ACS 20

Figure 6: Investigation and treatment algorithm. 21

Figure 7: Treatment and Management of ACS 28

Figure 8: ACS Therapeutics Market, Global, Revenue ($m), 2005–2010 35

Figure 9: ACS Therapeutics Market, Global, Forecast ($m), 2010–2018 36

Figure 10: ACS Therapeutics Market, The US, Revenue ($m), 2005–2010 38

Figure 11: ACS Therapeutics Market, The US, Forecast ($m), 2010–2018 39

Figure 12: ACS Therapeutics Market, France, Revenue ($m), 2005–2010 40

Figure 13: ACS Therapeutics Market, France, Forecast ($m), 2010–2018 41

Figure 14: ACS Therapeutics Market, Germany, Revenue ($m), 2005–2010 43

Figure 15: ACS Therapeutics Market, Germany, Forecast ($m), 2010–2018 44

Figure 16: ACS Therapeutics Market, Italy, Revenue ($m), 2005–2010 45

Figure 17: ACS Therapeutics Market, Italy, Forecast ($m), 2010–2018 46

Figure 18: ACS Therapeutics Market, Spain, Revenue ($m), 2005–2010 48

Figure 19: ACS Therapeutics Market, Spain, Forecast ($m), 2010–2018 49

Figure 20: ACS Therapeutics Market, The UK, Revenue ($m), 2005–2010 50

Figure 21: ACS Therapeutics Market, The UK, Forecast ($m), 2010–2018 51

Figure 22: ACS Therapeutics Market, Japan, Revenue ($m), 2005–2010 53

Figure 23: ACS Therapeutics Market, Japan, Forecast ($m), 2010–2018 54

Figure 24: Opportunity and Unmet Need in the ACS Therapeutics Market, 2011 58

Figure 25: Strategic Competitor Assessment, 2011 61

Figure 26: Technology Trends Analytics Frame Work, 2011 86

Figure 27: Technology Trends Analytics Frame Work – Description, 2011 87

Figure 28: Acute Coronary Syndrome Market – Clinical Pipeline by Mechanism of Action, 2011 98

Figure 29: ACS Therapeutics Market – Clinical Pipeline by Phase of Development, 2011 99

Figure 30: ACS Therapeutics, Global, Clinical Trials by Country, 2011 102

Figure 31: ACS Therapeutics, Global, Clinical Trials by Phase (%), 2011 103

Figure 32: ACS Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 104

Figure 33: ACS Therapeutics, Global, Overall Sponsors (%), 2011 105

Figure 34: ACS Therapeutics, Global, Prominent Sponsors (%), 2011 106

Figure 35: ACS Therapeutics, Global, Top Ten Companies by Phase, 2011 107

Figure 36: ACS Therapeutics Market, Drivers and Barriers, 2011 109

Figure 37: Implications for Future Market Competition in the ACS Therapeutics Market, 2011 110

Figure 38: ACS Therapeutics Market – Clinical Pipeline by Company, 2011 112

Figure 39: GlobalData Market Forecasting Model 137GlaxoSmithKline Plc

F. Hoffmann-La Roche

Anthera Pharmaceuticals

Novartis A G

Sanofi

Johnson & Johnson

Bayer AG

The Medicines Company

Eisai Co., Ltd.

Portola Pharmaceuticals, Inc.

To order this report:

Pathology Industry: Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com